Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Germany
/
Pharmaceuticals & Biotech
/
Bayer
BAYN
Bayer
Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
09 Jun 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€23.00
24.2% overvalued
intrinsic discount
20 Aug
€28.56
Loading
1Y
2.5%
7D
5.6%
Author's Valuation
€23.0
24.2% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€23.0
24.2% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-16b
50b
2014
2017
2020
2023
2025
2026
2028
Revenue €46.0b
Earnings €2.6b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
1.42%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.10%
Calculation
€2.60b
Earnings '28
x
10.08x
PE Ratio '28
=
€26.23b
Market Cap '28
€26.23b
Market Cap '28
/
982.42m
No. shares '28
=
€26.70
Share Price '28
€26.70
Share Price '28
Discounted to 2025 @ 5.11% p.a.
=
€22.99
Fair Value '25